Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs

DIB, A.; PAREDES, A.; ELIOPOLUS,N; FARIAS, C; SUAREZ, G.; ALDROVANDI,; PALMA S.; SANCHEZ BRUNI SF

Clinical and Experimental Pharmacology

OMICS

Año: 2015 vol. 5 p. 198 - 203

The aim of this study was to obtain five novel Ricobendazole (RBZ)-based formulations (one immediate and four controlled-release) with the most convenient release rates and test their correlation in vitro-in vivo. Hydroxypropyl Methyl Cellulose (HPMC), Cetyl Alcohol, Gelucire 50/02® and Alginic Acid were used as main excipients for CR formulations. Pharmacotechnical quality control tests were successfully completed. One albendazole (ABZ)-based immediate-release formulation was used as reference. Twelve dogs were randomly divided into six groups (n=2) using an incomplete block design. Oral treatments (capsules) were carried out in two phases. Phase I: treatment ?A? (ABZ-based immediate-release formulation {25 mg/kg}). Treatment ?B? (RBZ-based immediate-release formulation) and treatments from ?C? to ?F? (CR formulations {20 mg/kg}). After 21 days of wash-out period, the experiment was repeated as Phase II. Blood samples were collected over 48 h and analysed by high performance liquid chromatography. The ABZSO pharmacokinetic (PK) disposition of RBZ formulations was greater (p= 0,05). The CR formulations did not correlate the obtained in vitro controlled release behaviour with that of in vivo. This work would contribute to identify other matrices developers in RBZ- CR formulations.